

**IN THE UNITED STATES DISTRICT COURT  
FOR THE WESTERN DISTRICT OF OKLAHOMA**

CHARLES LEON MANOUS, Surviving  
Spouse and Personal Representative of the  
Estate of Carol Ann Manous, deceased

Plaintiff,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant.

Case No. 5:11-cv-01330-R

**DEFENDANT'S EXHIBIT LIST**

AND NOW COMES Defendant, Mylan Pharmaceuticals Inc. ("Mylan"), by and through its undersigned counsel, and in accordance with the applicable Scheduling Order (see Docket No. 31),<sup>1</sup> hereby files its Exhibit List. Mylan reserves the right to use any of the following documents, items, or tangible things as exhibits during the trial of this matter:<sup>2</sup>

EXHIBIT NO.	DESCRIPTION
1.	Report from the Mylan Clinical Study identified as FENT Study 9884
2.	Data compilations of the drug concentrations observed during FENT Study 9884
3.	Graphs/Charts plotting drug concentrations observed during FENT Study 9884
4.	Report from the Mylan Clinical Study identified as FENT Study 0156
5.	Data compilations of the drug concentrations observed during FENT Study 0156
6.	Graphs/Charts plotting drug concentrations observed during FENT Study 0156
7.	Report from the Mylan Clinical Study identified as FENT Study 0105
8.	Data compilations of the drug concentrations observed during FENT Study 0105
9.	Graphs/Charts plotting drug concentrations observed during FENT Study 0105
10.	Report from the Mylan Clinical Study identified as FENT Study 04108

<sup>1</sup> Deadlines relating to service of witness and exhibit lists, and objections thereto, were not affected by the Court's grant of Mylan's Agreed Motion to Amend Scheduling Order. (See Docket No. 40.)

<sup>2</sup> Mylan is not offering these exhibits into evidence at this time. What Mylan ultimately moves to have admitted into evidence depends upon the issues Plaintiff raises during the trial of this case. The question of what documents and exhibits will be relevant can only be determined based on the issues presented at time of trial. Thus, by listing such exhibits in this filing, Mylan does not concede the admissibility of the same into evidence. Moreover, Mylan reiterates that the confidentiality of any Mylan document is not waived simply by listing the same on this exhibit list.

EXHIBIT NO.	DESCRIPTION
11.	Data compilations of the drug concentrations observed during FENT Study 04108
12.	Graphs/Charts plotting drug concentrations observed during FENT Study 04108
13.	Report from the Mylan Clinical Study identified as FENT Study 0623
14.	Data compilations of the drug concentrations observed during FENT Study 0623
15.	Graphs/Charts plotting drug concentrations observed during FENT Study 0623
16.	Report from the Mylan Clinical Study identified as FENT Study 05128
17.	Data compilations of the drug concentrations observed during FENT Study 05128
18.	Graphs/Charts plotting drug concentrations observed during FENT Study 05128
19.	Report from the Mylan Clinical Study identified as FENT Study 06102
20.	Data compilations of the drug concentrations observed during FENT Study 06102
21.	Graphs/Charts plotting drug concentrations observed during FENT Study 06102
22.	Report from the Mylan Clinical Study identified as FENT Study 06104
23.	Data compilations of the drug concentrations observed during FENT Study 06104
24.	Graphs/Charts plotting drug concentrations observed during FENT Study 06104
25.	Report from the Mylan Clinical Study identified as FENT Study 09528
26.	Data compilations of the drug concentrations observed during FENT Study 09528
27.	Graphs/Charts plotting drug concentrations observed during FENT Study 09528
28.	Report from the Mylan Clinical Study identified as FENT Study 08120
29.	Data compilations of the drug concentrations observed during FENT Study 08120
30.	Graphs/Charts plotting drug concentrations observed during FENT Study 08120
31.	Report from the Mylan Clinical Study identified as FENT Study 08133
32.	Data compilations of the drug concentrations observed during FENT Study 08133
33.	Graphs/Charts plotting drug concentrations observed during FENT Study 08133
34.	Report from the Mylan Clinical Study identified as FENT Study 09108
35.	Data compilations of the drug concentrations observed during FENT Study 09108
36.	Graphs/Charts plotting drug concentrations observed during FENT Study 09108
37.	Report from the Mylan Clinical Study identified as FENT Study 0155
38.	Data compilations of the drug concentrations observed during FENT Study 0155
39.	Graphs/Charts plotting drug concentrations observed during FENT Study 0155
40.	Report from the Mylan Clinical Study identified as FENT Study 0406
41.	Data compilations of the drug concentrations observed during FENT Study 0406
42.	Graphs/Charts plotting drug concentrations observed during FENT Study 0406
43.	Report from the Mylan Clinical Study identified as FENT Study 1076
44.	Data compilations of the drug concentrations observed during FENT Study 1076
45.	Graphs/Charts plotting drug concentrations observed during FENT Study 1076
46.	Report from the Mylan Clinical Study identified as FENT Study 10114
47.	Data compilations of the drug concentrations observed during FENT Study 10114
48.	Graphs/Charts plotting drug concentrations observed during FENT Study 10114
49.	Report from the Mylan Clinical Study identified as FENT Study 10113
50.	Data compilations of the drug concentrations observed during FENT Study 10113
51.	Graphs/Charts plotting drug concentrations observed during FENT Study 10113
52.	Graphs/Charts plotting drug concentrations observed during Fentanyl Combined Studies involving the 25 mcg/hr Mylan Fentanyl Transdermal System®

EXHIBIT NO.	DESCRIPTION
53.	Graphs/Charts plotting drug concentrations observed during Fentanyl Combined Studies involving the 100 mcg/hr Mylan Fentanyl Transdermal System®
54.	Abbreviated New Drug Application for the Mylan Fentanyl Transdermal System®
55.	January 28, 2005 letter from the FDA approving the Mylan Fentanyl Transdermal System® as a safe and effective drug product
56.	Sub-Exhibit 56-1: Demonstrative aid illustrating the dissolving of fentanyl “crystals” and the subsequent absorption of molecules through the skin
	Sub-Exhibit 56-2: Demonstrative aid illustrating the barrier properties of the skin which ensures consistent delivery of fentanyl from the MFTS
	Sub-Exhibit 56-3: Demonstrative aid illustrating the diffusion of molecules through the skin from a MFTS
57.	Exemplar Mylan Fentanyl Transdermal Systems®
58.	Sub-Exhibit 58-1: Demonstrative aid representing a MFTS box, pouch, and layers
	Sub-Exhibit 58-2: Demonstrative aid highlighting FDA’s determination that the MFTS is “safe and effective”
	Sub-Exhibit 58-3: Demonstrative aid depicting the monolithic matrix design utilized in the MFTS
	Sub-Exhibit 58-4: Demonstrative aid depicting the components of the monolithic matrix design utilized in the MFTS
	Sub-Exhibit 58-5: Photograph of 100 mcg/hr MFTS
	Sub-Exhibit 58-6: Demonstrative aid highlighting the safety advantages of the matrix design
59.	Sub-Exhibit 59-1: Demonstrative aid reflecting the pH scale of commonly-found substances, including human blood
	Sub-Exhibit 59-2: Demonstrative aid demonstrating that fentanyl resists dissolving in “alive” blood
	Sub-Exhibit 59-3: Demonstrative aid demonstrating that, at death, pH drops and blood solubility increases
	Sub-Exhibit 59-4: Demonstrative aid introducing concepts of postmortem redistribution as influenced by changes in the solubility level of blood
	Sub-Exhibit 59-5: Demonstrative aid introducing concepts of postmortem redistribution as influenced by changes in the solubility level of “live” blood
	Sub-Exhibit 59-6: Demonstrative aid highlighting Baselt conclusion that fentanyl undergoes postmortem redistribution
	Sub-Exhibit 59-7: Demonstrative aid outlining “lipophilic” properties of fentanyl in reference to Baselt’s text
	Sub-Exhibit 59-8: Demonstrative aid reflecting the effect of pH changes in blood on fentanyl concentrations in reference to the Olson (2010) paper
60.	Chart identifying the medications used by Carol Ann Manous (based on date prescribed)
	Sub-Exhibit 60-1: Chart identifying the medications used by Carol Ann Manous (no date reference)
61.	The full prescribing information for the Mylan Fentanyl Transdermal System® (FTS:R17)

EXHIBIT NO.	DESCRIPTION
62.	The Medication Guide for the Mylan Fentanyl Transdermal System® (FTS:R17)
63.	Sub-Exhibit 63-1: Photograph of the Duragesic® (reservoir)
	Sub-Exhibit 63-2: Demonstrative aid depicting the layers of a reservoir patch design
	Sub-Exhibit 63-3: Demonstrative aid highlighting the characteristics of a reservoir patch design
64.	Sub-Exhibit 64-1: Demonstrative aid representing a MFTS box, pouch, and layers
	Sub-Exhibit 64-2: Demonstrative aid depicting the monolithic matrix design utilized in the MFTS
	Sub-Exhibit 64-3: Demonstrative aid depicting a “cutaway” of a simple monolithic matrix patch
	Sub-Exhibit 64-4: Demonstrative aid depicting the components of the monolithic matrix design utilized in the MFTS
	Sub-Exhibit 64-5: Photograph of 100 mcg/hr MFTS
	Sub-Exhibit 64-6: Demonstrative aid illustrating the dissolving of fentanyl “crystals” and the subsequent absorption of molecules through the skin
	Sub-Exhibit 64-7: Demonstrative aid illustrating the diffusion of molecules through the skin from a MFTS
65.	Sub-Exhibit 65-1: Photograph of 100 mcg/hr MFTS
	Sub-Exhibit 65-2: Demonstrative aid depicting the monolithic matrix design utilized in the MFTS
	Sub-Exhibit 65-3: Demonstrative aid depicting the layers of the monolithic matrix design utilized in the MFTS
66.	Sub-Exhibit 66-1: Photograph of the Duragesic® (reservoir)
	Sub-Exhibit 66-2: Demonstrative aid depicting the layers of a reservoir patch design
	Sub-Exhibit 66-3: Photograph of 100 mcg/hr MFTS
	Sub-Exhibit 66-4: Demonstrative aid explaining the layers of a monolithic matrix design and the functions of the adhesive layer
	Sub-Exhibit 66-5: Graph plotting fentanyl plasma concentrations in living subjects over 144-hours during use of the Mylan Fentanyl Transdermal System®
	Sub-Exhibit 66-6: Graph plotting fentanyl plasma concentrations in living subjects over 144-hours during use of the Duragesic® (reservoir)
	Sub-Exhibit 66-7: Graph co-plotting fentanyl plasma concentrations in living subjects over 144-hours during use of the Mylan Fentanyl Transdermal System® and the Duragesic® (reservoir) demonstrating bioequivalence despite different designs
	Sub-Exhibit 66-8: Table comparing characteristics of the reservoir and matrix designs
	Sub-Exhibit 66-9: Demonstrative aid highlighting the safety advantages of the matrix design
	Sub-Exhibit 66-10: Bar graph depicting FDA approved and marketed transdermal products by release technology employed
	Sub-Exhibit 66-11: Pie charts depicting the number of approved or pending drugs by release technology employed, demonstrating that the matrix design is preferred
	Sub-Exhibit 66-12: Photograph of Duragesic® (matrix) design, demonstrating that the branded manufacturer has now switched to a matrix design

EXHIBIT NO.	DESCRIPTION
67.	Sub-Exhibit 67-1: Bar graph depicting FDA approved and marketed transdermal products by release technology employed
	Sub-Exhibit 67-2: Pie charts depicting the number of approved or pending drugs by release technology employed, demonstrating that the matrix design is preferred
	Sub-Exhibit 67-3: Photograph of Duragesic® (matrix) design, demonstrating that the branded manufacturer has now switched to a matrix design
68.	Chart listing medications used by Carol Ann Manous by class/properties
69.	Demonstrative representation of the FDA-approved labeling for the Mylan Fentanyl Transdermal System® illustrating the number of warnings given regarding the risk of fatal, deadly or life-threatening consequences associated with the failure to carefully use this medication
70.	Anderson, D.T., and Muto, Joseph J., Duragesic® Transdermal Patch: Postmortem Tissue Distribution of Fentanyl in 25 Cases
	Sub-Exhibit 70-1: Demonstrative aid excerpting Anderson study's analysis of postmortem redistribution
	Sub-Exhibit 70-2: Demonstrative aid excerpting analysis of Cases 11 and 16 from the Anderson study
	Sub-Exhibit 70-3: Demonstrative aid reflecting data stemming from Cases 11 and 16 from the Anderson study
	Sub-Exhibit 70-4: Demonstrative aid reflecting the dangers of polypharmacy highlighted in the Anderson study
71.	Calis, K.A., Transdermally Administered Fentanyl for Pain Management
72.	Cartwright, P., Ventilatory Depression Related to Plasma Fentanyl Concentrations During and After Anesthesia in Humans
73.	Cole, J.M., Variability of Transdermal Fentanyl Metabolism and Excretion in Pain Patients
74.	Cook, D.S., Estimating Antemortem drug concentrations from postmortem blood samples: the influence of postmortem redistribution
75.	Skopp, G., Artifacts Are an Inherent Part of Postmortem Toxicology
76.	Edinboro, L.E., Fatal Fentanyl Intoxication Following Excessive Transdermal Application
77.	Fiset, P., Biopharmaceutics of a New Transdermal Fentanyl Device
78.	Gourlay, G.K., Fentanyl Blood Concentration-Analgesic Response Relationship in Treatment of Postoperative pain
79.	Isenschmid, D.S., A Rapid Increase in Fentanyl-Related Deaths in Detroit – A Twelve Month Review
80.	Jones, G.R., Interpretation of Postmortem Drug Levels
81.	Larsen, R.H., Dermal Penetration of Fentanyl: Inter and Intraindividual Variations
82.	Lilleng, P.K., Deaths After Intravenous Misuse of Transdermal Fentanyl
83.	Luckenbill, K., Fentanyl Postmortem Redistribution: Preliminary Findings regarding the Relationship Among Femoral Blood and Liver and Heart Tissue Concentrations
84.	Martin, T.L., Fentanyl Related Deaths in Ontario, Canada: Toxicological Findings and Circumstances of Death in 112 Cases (2002-2004)
85.	Menahem, S., High-dose fentanyl patch for cancer pain

EXHIBIT NO.	DESCRIPTION
86.	Noonan, P.J., Pharmacokinetics and the Variability of Percutaneous Absorption
87.	Pounder, D.J., Post-Mortem Drug Redistribution – A Toxicological Nightmare
88.	Prouty, R.W., The Forensic Science Implications of Site and Temporal Influences on Postmortem Blood-Drug Concentrations
89.	Roy, S.D., Solubility and Related Physicochemical Properties of Narcotic Analgesics
90.	Roy, S.D., Solubility Behavior of Narcotic Analgesics in Aqueous Media: Solubilities and Dissociation Constants of Morphine, Fentanyl and Sufentanil
91.	Roy, S.D., Transdermal Delivery of Narcotic Analgesics: Comparative Permeabilities of Narcotic Analgesics Through Human Cadaver Skin
92.	Roy, S.D., Transdermal Delivery of Narcotic Analgesics: pH, Anatomical, and Subject Influences on Cutaneous Permeability of Fentanyl and Sufentanil
93.	Schmidt, C., Investigation of the Postmortem Redistribution of Opiates
94.	Shepherd, M.F., Postmortem Changes and Pharmacokinetics: Review of the Literature and Case Report
95.	Rodda, K.E., The Redistribution of Selected Psychiatric Drugs in Post-Mortem Cases
96.	Thompson, J.G., Fentanyl Concentrations in 23 Postmortem Cases from the Hennepin County Medical Examiner's office
97.	Woodall, Karen L., et al., Oral Abuse of Fentanyl Patches (Duragesic): Seven Case Reports
	Sub-Exhibit 97-1: Demonstrative aid excerpting the Woodall study's analysis of Case 5
	Sub-Exhibit 97-2: Demonstrative aid highlighting dangers of polypharmacy as reflected in the Woodall study
98.	Barnhart, F.E., Bonnell, H.J., Rossum, K.M., Postmortem drug redistribution. Forensic Sci. Rev. 201; 13:101-129
99.	Bleeker, C.P., Bremer, R.C., Dongelmans, D.A., et al., Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur. J. Pain. 2001; 5:323-329
100.	Palmer, R.B., Fentanyl in postmortem forensic toxicology. Clin. Toxicol., 2010:771-784
101.	Ceelen, L., Postmortem Redistribution of Fentanyl in the Rabbit Blood, Am. J. Forensic Med. Pathol., 2010
102.	Dalpe-Scott, et al., A comparison of drug concentrations in postmortem cardiac and peripheral blood in 320 cases. Can. Soc. Forensic Sci. J. 1995; 28:113-121
103.	Drummer, O.H., Post-mortem toxicology, Forensic Sci. Int. 2007; 165:199-203
104.	FDA Publication - Fentanyl Transdermal System (marketed as Duragesic®). Patient Information Sheet. 2005; 1-3
105.	FDA Publication - Fentanyl Transdermal Patch (marketed as Duragesic). FDA Alert for Healthcare Professionals, July 2005
106.	FDA Publication - FDA Issues Public Health Advisory on the Fentanyl Patch. FDA Statement, July 2005
	Sub-Exhibit 106-1: FDA Publication – FDA News Release regarding Public Health Advisory. FDA News Release, July 2005

EXHIBIT NO.	DESCRIPTION
107.	FDA Publication - Information for Healthcare Professionals Fentanyl Transdermal System (marketed as Duragesic and generics). FDA Alert, December 2007
108.	FDA Publication - Important Information for the Safe Use of Fentanyl Transdermal System (Patch). FDA Public Health Advisory, December 2007
109.	FDA Publication - FDA issues second safety warning on fentanyl skin patch: Deaths and serious injuries from improper use. FDA News Release, December 2007
110.	Gourlay, G.K., Kowaski, S.R., Plummer, J.L., et al., The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects. Pain. 1989; 37:193-202
111.	Gourlay, G.K., Kowalski, S.R., Plummer, J.L., et al., The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain. 1990; 40:21-28
112.	Gourlay, G.K., Kowalski, S.R., Plummer, J.L., et al., Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth. Analg. 1998; 67:329-337
113.	Janssen Pharmaceutica Products L. Duragesic (Fentanyl Transdermal System): Full Prescribing Information. Janssen Pharmaceutica Products, LP, Titusville, NJ (Revised April 2007)
114.	Janssen Pharmaceutica Products L. Dear Healthcare Professional (Letter): Important Drug Warning. Janssen Pharmaceutica Products, LP, Titusville, NJ, June 2005
115.	Janssen Pharmaceutica Products L. Fentanyl Transdermal System: Full prescribing information and patient information
116.	Jeal, W., Benfield, P., Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control, Drugs, 1997; 53:109-138
117.	Karch, S.B., Is post-mortem toxicology quackery? J. Clin. Forensic Med. 2003; 10:197-198
118.	Karch, S.B., Fentanyl. In: Karch, SB, ed. Karch's Pathology of Drug Abuse, 4 <sup>th</sup> Ed., Boca Raton, FL. CRC Press 2009; 444-455
119.	Kuhlman, Jr., J.J., McCauley, R., Valouch, T.J., et al., Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J. Anal. Toxicol. 2003; 27:499-504
	Sub-Exhibit 119-1: Demonstrative aid highlighting the dangers of polypharmacy as reflected in the Kuhlman study
120.	Langford, A.M., Pounder, D.J., Possible markers for postmortem drug redistribution, J. Forensic Sci. 1997; 42:88-92
121.	Martin, T.L., Woodall, K.L., McLellan, B.A., Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004), J. Anal. Toxicol. 2006; 30:603-610
	Sub-Exhibit 121-1: Demonstrative aid highlighting the dangers of polypharmacy as reflected in the Martin study
122.	Maves, T.J., Barcellos, W.A., Management of cancer pain with transdermal fentanyl: phase IV trial, University of Iowa. J. Pain Symptom Manage. 1992; 7:S58-62
123.	Miguel, R., Kreitzer, J.M., Reinhart, D., et al., Postoperative pain control with a new transdermal fentanyl delivery system. A multicenter trial. Anesthesiology, 1995; 83:470-477

EXHIBIT NO.	DESCRIPTION
124.	Mozayani, M., Danielson, T., Sanchez, L.A., Interpretation of fentanyl in postmortem cases (abstract #K9), American Academy of Forensic Sciences (AAFS), 2008; Annual Meeting, Washington, DC
125.	Olson, K.N., Luckenbill, K., Thompson, J., et al., Postmortem redistribution of fentanyl in blood, Am. J. Clin. Pathol. 2010; 133:447-453
126.	Andresen, Hilke, et al., Fentanyl: Toxic or Therapeutic? Postmortem and Antemortem Blood Concentrations After Transdermal Fentanyl Application, Journal of Analytical Toxicology, 2012; 36:182-94
127.	Oliveira, Gabriela, et al., Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch, Toxicology in Vitro, June 2012; 26:645-48
128.	Gill, James, R., et al., Reliability of Postmortem Fentanyl Concentrations in Determining the Cause of Death, Journal of Medical Toxicology, 2013; 9:34-41
129.	FDA Establishment Inspection Report - 2002
130.	FDA Establishment Inspection Report - 2005
131.	FDA Establishment Inspection Report - 2008
132.	Exemplar carton and pouch for the Mylan Fentanyl Transdermal System®
133.	PowerPoint Slides depicting the manufacturing process employed at Mylan Technologies Inc. in the production of the Mylan Fentanyl Transdermal System®
134.	The Mylan Formulation Development Report for the Mylan Fentanyl Transdermal System®
135.	Documents recording Mylan communications with the FDA on February 12, 2008 concerning Mylan's ability to supply the entire fentanyl market
136.	The Condensed Development Report for the Mylan Fentanyl Transdermal System®
137.	NDA 19-813 Summary Basis of Approval of Duragesic®
138.	Diagrams and pictorials depicting a cross-section of human skin
139.	Diagrams and pictorials depicting the stratum corneum
140.	Baselt Monograph for Fentanyl
141.	Baselt Monograph for Oxycodone
142.	FDA Full Prescribing Information for Oxycodone
143.	Baselt Monograph for Klonopin
144.	FDA Full Prescribing Information for Klonopin
145.	Baselt Monograph for Neurontin
146.	FDA-approved Full Prescribing Information for Neurontin
147.	Baselt Monograph for Tizanidine
148.	FDA-approved Full Prescribing Information for Tizanidine
149.	Baselt Monograph for Lexapro
150.	FDA-approved Full Prescribing Information for Lexapro
151.	Baselt Monograph for Nuvigil
152.	FDA-approved Full Prescribing Information for Nuvigil
153.	Baselt Monograph for Travatan
154.	FDA-approved Full Prescribing Information for Travatan
155.	Baselt Monograph for Timolol
156.	FDA-approved Full Prescribing Information for Timolol



EXHIBIT NO.	DESCRIPTION
157.	Compiled Data from In Vitro Flux Studies
158.	Sub-Exhibit 158-1: 2010 Calendar
	Sub-Exhibit 158-2: 2009 Calendar
159.	Sub-Exhibit 159-1: Centers for Disease Control and Prevention Weekly Report (November 4, 2011), "Vital Signs: Overdoses of Prescription Opioid Pain Relievers – United States, 1999-2008"
	Sub-Exhibit 159-2: Morbidity and Mortality Weekly Report (November 1, 2011), "Vital Signs: Overdoses of Prescription Opioid Pain Relievers – United States, 1999-2008"
160.	Prodduturi, S., et al., Transdermal delivery of fentanyl from matrix and reservoir systems: Effect of heat and compromised skin
161.	Sub-Exhibit 161-1: Background of New Mexico Study re: Postmortem Redistribution of Fentanyl by Krinsky, C., et al.
	Sub-Exhibit 161-2: Description of Samples from New Mexico Study
	Sub-Exhibit 161-3: Fentanyl Concentration Chart from New Mexico Study
	Sub-Exhibit 161-4: Evidence of Postmortem Redistribution from New Mexico Study
	Sub-Exhibit 161-5: Analysis of Evidence of Postmortem Redistribution from New Mexico Study
	Sub-Exhibit 161-6: Conclusions from New Mexico Study
162.	Krinsky, Clarissa S., Lathrop, Sarah L., Crossey, Michael, Baker, Ginger, and Zumwalt, Ross, "A Toxicology-Based Review of Fentanyl-Related Deaths in New Mexico (1986-2007)"
163.	Expert Report of Robert Palmer, Ph.D.
164.	Curriculum Vitae of Robert Palmer, Ph.D.
165.	Expert Report of Gordon Flynn, Ph.D.
166.	Curriculum Vitae of Gordon Flynn, Ph.D.
167.	Expert Report of Mark Wallace, M.D.
168.	Curriculum Vitae of Mark Wallace, M.D.
169.	Expert Report of Thomas Wheeler, M.D.
170.	Curriculum Vitae of Thomas Wheeler, M.D.
171.	Transcript of the Deposition of Byron Curtis, Ph.D., taken 12/12/12
172.	Correction Sheet to the Transcript of the Deposition of Byron Curtis, Ph.D., taken 12/12/12
173.	Exhibit 8 to the Deposition of Byron Curtis, Ph.D., taken 12/12/12 (Interrogatories)
174.	Exhibit 9 to the Deposition of Byron Curtis, Ph.D., taken 12/12/12 (Toxicology File)
175.	Transcript of the Deposition of Marius Tarau, M.D., taken 12/11/12
176.	Exhibit 2 to the Deposition of Marius Tarau, M.D., taken 12/11/12 (Report of Investigation by Medical Examiner)
177.	Exhibit 3 to the Deposition of Marius Tarau, M.D., taken 12/11/12 (Andresen Paper)
178.	Exhibit 4 to the Deposition of Marius Tarau, M.D., taken 12/11/12 (Newcastle Police Incident Report)
179.	Exhibit 5 to the Deposition of Marius Tarau, M.D., taken 12/11/12 (Winecker Tables)

EXHIBIT NO.	DESCRIPTION
180.	Exhibit 6 to the Deposition of Marius Tarau, M.D., taken 12/11/12 (File Materials)
181.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
182.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
183.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
184.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
185.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
186.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
187.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
188.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
189.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
190.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
191.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
192.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
193.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
194.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
195.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
196.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
197.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
198.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
199.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
200.	*** RESERVED FOR IDENTIFICATION OF ADDITIONAL DEPOSITION TRANSCRIPTS AND/OR EXHIBITS ***
201.	Records received via HIPAA Authorization from Jeanette Padgett, M.D.
202.	Records received via HIPAA Authorization from Diagnostic Laboratory of Oklahoma

EXHIBIT NO.	DESCRIPTION
203.	Records received via HIPAA Authorization from LakePoint Imaging Center & Open MRI and/or Chris Degner, M.D.
204.	Records received via HIPAA Authorization from Ocular Physicians Associates, PLLC and/or John P. Belardo, M.D.
205.	Records received via HIPAA Authorization from Surgery Center of Oklahoma and/or Russell Hanan, Jr., M.D.
206.	Records received via HIPAA Authorization from Oklahoma PainCare Inc. and/or Michael Schwartz, M.D.
207.	Records received via HIPAA Authorization from MS Center of Oklahoma and/or Gabriel Pardo, M.D.
208.	Records received via HIPAA Authorization from Women's HealthCare of Norman and/or Daphne Lashbrook, M.D.
209.	Records received via HIPAA Authorization from Vitacare Home Medical Equipment
210.	Records received via HIPAA Authorization from Norman Regional Health System
211.	Records received via HIPAA Authorization from Norman Clinic, Inc. and/or Farhat Husain, M.D.
212.	Records received via HIPAA Authorization from Blanchard Family Medicine and/or Mark Winchester, M.D. and/or Ryan Turner, M.D.
213.	Records received via HIPAA Authorization from Wal-Mart
214.	Records received via HIPAA Authorization from Walgreen's
215.	Records received via HIPAA Authorization from CVS
216.	Records received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma regarding Case No. 1000968 (Report of Investigation by Medical Examiner, et al.)
217.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 1 of 10)
218.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 2 of 10)
219.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 3 of 10)
220.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 4 of 10)
221.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 5 of 10)
222.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 6 of 10)
223.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 7 of 10)
224.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 8 of 10)
225.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 9 of 10)
226.	Photograph received via HIPAA Authorization from the Office of the Chief Medical Examiner of Oklahoma (No. 10 of 10)

EXHIBIT NO.	DESCRIPTION
227.	Records received via HIPAA Authorization from the Board of Medicolegal Investigations of the Office of the Chief Medical Examiner of Oklahoma regarding Laboratory No. 10-0906 (Report of Laboratory Analysis, Litigation Packet, et al.)
228.	Records received via HIPAA Authorization from Newcastle Police Department
229.	Records received via HIPAA Authorization from Newcastle Fire Department
230.	Plaintiff's Responses to Defendant's First Request for Production of Documents Directed to Plaintiff
231.	Documents Produced by Plaintiff in Response to Defendant's First Request for Production of Documents Directed to Plaintiff
232.	Plaintiff's Responses to Defendant's First Set of Interrogatories Directed to Plaintiff
233.	Plaintiff's Rule 26(a)(1) Initial Disclosures
234.	Certificate of Death received via Plaintiff's Rule 26(a)(1) Initial Disclosures
235.	Photographs of Box received via Plaintiff's Rule 26(a)(1) Initial Disclosures
236.	Report of Investigation by Medical Examiner received via Plaintiff's Rule 26(a)(1) Initial Disclosures
237.	Walgreen's Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
238.	Letters of Administration received via Plaintiff's Rule 26(a)(1) Initial Disclosures
239.	Blanchard Family Medicine Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
240.	Oklahoma PainCare Inc. Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
241.	MS Center of Oklahoma Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
242.	FTS:R17 Labeling received via Plaintiff's Rule 26(a)(1) Initial Disclosures
243.	Eisenhower Funeral Home Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
244.	Wal-Mart Records received via Plaintiff's Rule 26(a)(1) Initial Disclosures
245.	Batch Records, FTS Lot 6A0045
246.	Paulozzi, L., et al., A History of Being Prescribed Controlled Substances and Risk of Drug Overdose Death, Pain Med., Jan. 2012; 13:87-95
247.	Bohnert, A., et al., Association Between Opioid Prescribing Patterns and Opioid Overdose Related Deaths, JAMA, April 6, 2011; 305:1315-1321
248.	Manchikanti, L., et al., Opioid Epidemic in United States, Pain Physician, July 2012; 15(3 Supp.):ES9-38
249.	Medical and scientific literature detailing the risks of polypharmacy
250.	Janssen/Duragesic Recall Notice regarding reservoir fentanyl patches (February 2004)
251.	Janssen/Duragesic Recall Notice regarding reservoir fentanyl patches (April 2004)
252.	Pricara/Duragesic/Sandoz Recall Notice regarding reservoir fentanyl patches (February 2008)
253.	Actavis Recall Notice regarding reservoir fentanyl patches (February 2008)
254.	Actavis Recall Notice regarding reservoir fentanyl patches (March 2008)
255.	Watson Recall Notice regarding reservoir fentanyl patches (March 2008)
256.	Watson Recall Notice regarding reservoir fentanyl patches (August 2008)

EXHIBIT NO.	DESCRIPTION
257.	PriCara Recall Notice regarding reservoir fentanyl patches (December 2008)
258.	Watson Recall Notice regarding reservoir fentanyl patches (August 2009)
259.	Flynn, G., Citizen Petition, FDA Docket 2005P-0441 (October 13, 2005)
260.	FDA Publication – Consolidated Response to Citizen Petitions, FDA Docket 2004P-0506/CP1, et al. (January 28, 2005)
261-499.	*** RESERVED ***

In addition to the above-listed exhibits, Mylan provides the following list of “conditional” exhibits. This conditional list of exhibits is prepared based on Plaintiff’s disclosure of trial exhibits, and may change based on additional documents, if any, offered by Plaintiff, or based upon the Court’s rulings on anticipated motions in limine:

EXHIBIT NO.	DESCRIPTION
500.	Analysis of Adverse Events Reported with Mylan’s Fentanyl Transdermal System, by Greg Burkhart, M.D., M.S., External Epidemiological Consultant (July 27, 2005)
501.	MFTS PSUR #1: January 28, 2005 – April 30, 2005
502.	MFTS PSUR #2: May 1, 2005 – July 31, 2005
503.	MFTS PSUR #3: August 1, 2005 – October 31, 2005
504.	MFTS PSUR #4: November 1, 2005 – January 31, 2006
505.	MFTS PSUR #5: February 1, 2006 – April 30, 2006
506.	MFTS PSUR #6: May 1, 2006 – July 31, 2006
507.	MFTS PSUR #7: August 1, 2006 – October 31, 2006
508.	MFTS PSUR #8: November 1, 2006 – January 31, 2007
509.	MFTS PSUR #9: February 1, 2007 – April 31, 2007
510.	MFTS PSUR #10: May 1, 2007 – July 31, 2007
511.	MFTS PSUR #11: August 1, 2007 – October 31, 2007
512.	MFTS PSUR #12: November 1, 2007 – January 31, 2008
513.	MFTS PSUR #13: February 1, 2008 – January 31, 2009
514.	MFTS PSUR #14: February 1, 2009 – January 31, 2010
515.	The complete Adverse Event Files for any specific AE Report/MedWatch Report Plaintiff seeks to introduce
516.	Sub-Exhibit 516-1: FDA Reported Fatal Adverse Events Involving Transdermal Fentanyl by Market Share
	Sub-Exhibit 516-2: Fentanyl Related Deaths as Reported to FDA
517.	Charts/graphs depicting the numbers of fatal adverse event reports received by the FDA with respect to other narcotics
518.	Charts/graphs providing the comparative analysis of fatal Adverse Event reports for other pharmaceutical products, including Tylenol, Aspirin, and Penicillin

**RESERVATIONS**

In addition to the foregoing, Mylan reserves the right to use as an exhibit: (1) any document, item or tangible thing produced during the course of discovery; (2) any document, item or tangible thing identified on Plaintiff's exhibit list; (3) any of Decedent's medical, pharmacy, or employment records; and (4) any document, item, or tangible thing necessary to rebut or impeach any evidence or testimony offered by Plaintiff. Mylan reserves the right to supplement this Exhibit List any time up to and including the time of trial.

Dated: March 29, 2013

Respectfully submitted,

s/ Jason M. Reefer  
HALL, ESTILL, HARDWICK, GABLE,  
GOLDEN & NELSON, P.C.  
Jon Epstein, OBA # 13274  
Chase Tower  
100 North Broadway, Ste. 2900  
Oklahoma City, OK 73102-8865  
(405) 553-2828; (405) 553-2855 (F)

and

PIETRAGALLO, GORDON, ALFANO  
BOSICK & RASPANTI, LLP  
Clem C. Trischler, Esq.  
Jason M. Reefer, Esq.  
The Thirty-Eighth Floor  
One Oxford Centre  
Pittsburgh, PA 15219  
(412) 263-2000; (412) 261-5295 (F)  
*Attorneys for Defendant*

**CERTIFICATE OF SERVICE**

I hereby certify that a true and correct copy of the foregoing **Defendant's Exhibit List** was electronically transmitted to the Clerk of Court using the ECF System for filing on March 29, 2013. Based on the records currently on file, the Clerk of Court will transmit a Notice of Electronic Filing to the following ECF registrant:

L. Mark Bonner, OBA #14541  
NORMAN & EDEM, PLLC  
127 N.W. 10<sup>th</sup> St.  
Oklahoma City, OK 73103  
lmb@nemw.com  
*Attorney for Plaintiff*

By s/ Jason M. Reefer  
Jason M. Reefer